Literature DB >> 25548764

Tumor flare reaction in a patient with mantle cell lymphoma.

Yusuf Kayar1, Nuket Bayram Kayar2.   

Abstract

Entities:  

Year:  2014        PMID： 25548764      PMCID： PMC4278012          DOI： 10.5045/br.2014.49.4.279

Source DB:  PubMed          Journal:  Blood Res        ISSN： 2287-979X


× No keyword cloud information.
  5 in total

1.  Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.

Authors:  Heather E Eve; Simon A J Rule
Journal:  Br J Haematol       Date:  2010-09-29       Impact factor: 6.998

2.  Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma.

Authors:  Gaetano Corazzelli; Rosaria De Filippi; Gaetana Capobianco; Ferdinando Frigeri; Vincenzo De Rosa; Giancarla Iaccarino; Filippo Russo; Manuela Arcamone; Cristina Becchimanzi; Stefania Crisci; Gianpaolo Marcacci; Barbara Amoroso; Secondo Lastoria; Antonio Pinto
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

3.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Authors:  Asher Chanan-Khan; Kena C Miller; Laurie Musial; David Lawrence; Swaminathan Padmanabhan; Kenichi Takeshita; Carl W Porter; David W Goodrich; Zale P Bernstein; Paul Wallace; David Spaner; Alice Mohr; Catriona Byrne; Francisco Hernandez-Ilizaliturri; Cynthia Chrystal; Petr Starostik; Myron S Czuczman
Journal:  J Clin Oncol       Date:  2006-11-06       Impact factor: 44.544

4.  Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Authors:  Leslie A Andritsos; Amy J Johnson; Gerard Lozanski; William Blum; Cheryl Kefauver; Farrukh Awan; Lisa L Smith; Rosa Lapalombella; Sarah E May; Chelsey A Raymond; Da-Sheng Wang; Robert D Knight; Amy S Ruppert; Amy Lehman; David Jarjoura; Ching-Shih Chen; John C Byrd
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

5.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113
  5 in total
  2 in total

1.  Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.

Authors:  Mizuki Nishino
Journal:  J Immunother Cancer       Date:  2016-06-21       Impact factor: 13.751

2.  Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.

Authors:  Chunting Zhu; Yi Zhao; Fang Yu; Weijia Huang; Wenjun Wu; Jingsong He; Zhen Cai; Donghua He
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.